Summary
This article reviews multiple late-breaking clinical trials focusing on combination therapy and hospital utilization improvements. Specific trials include the phase 3 AMBITION [NCT01178073], the Comprehensive Respiratory Outcome Management program, as well as trials investigating the use of noninvasive open ventilation, end-of-rotation handoffs, and 2 phase 3 randomized controlled studies [NCT01957163; NCT02119286] looking at umeclidinium for the treatment of COPD.
- Nursing
- Acute Lung Injury & Respiratory Failure
- Pulmonary Clinical Trials Chronic Obstructive Pulmonary Disease
- Thromboembolic Disease
- Nursing
- Acute Lung Injury & Respiratory Failure
- Pulmonary Clinical Trials
- Pulmonary & Respiratory Medicine
- Chronic Obstructive Pulmonary Disease
- Thromboembolic Disease
- © 2014 MD Conference Express®
Tools
Successful Combination Therapies, Hospital Utilization Improvements among Late-Breaking Clinical Trials
Permalink:
Table of contents
- Article
- Summary
- MORTALITY INCREASES AND TRANSITION OF CARE
- INITIAL THERAPY WITH AMBRISENTAN PLUS TADALAFIL EFFECTIVE FOR PAH
- NONINVASIVE OPEN VENTILATION IMPROVES DYSPNEA AND RESPIRATORY SYMPTOMS
- NEW HEALTH MANAGEMENT SYSTEM REDUCES COST FOR PATIENTS WITH CHRONIC RESPIRATORY FAILURE
- COMBINATION THERAPY SAFE AND EFFECTIVE In MODERATE-TO-VERY-SEVERE COPD
- Info & Metrics
- eLetters
Cited By...
- No citing articles found.